SANTA ROSA, Calif., Feb. 3, 2015 /PRNewswire/ -- Dr. Isaac Eliaz, a widely respected integrative medical doctor and researcher, has been awarded a USA patent from the U.S. Patent and Trademark Office for his innovative combination of modified citrus pectin (MCP) and honokiol extract from magnolia tree bark. This combination has broad, multi-targeted potential to help stop the growth and spread of a variety of cancers.
Based on research and clinical observation, the combination of MCP and honokiol represents a significant step forward for cancer prevention and treatment efforts. Both MCP and honokiol are anti-cancer adjuvants that are safe and non-toxic. They can be taken orally as part of a daily regimen, and may be used to maintain cellular health, support conventional cancer treatments, and interrupt the metastatic spread of cancers already present within the body. Both MCP and honokiol have also demonstrated a number of additional benefits including anti-inflammatory actions, immune support, neurological protection and more.
"The use of MCP and honokiol in combination offers potential benefits for supporting the fight against cancer and enhancing existing cancer treatment efforts," said Dr. Eliaz. "The potential is significant for these compounds to assist with the administration of conventional anti-cancer therapies, including chemotherapeutic drugs, targeted growth factor inhibitors and radiation therapy. This patent approval will help spur further investigation into this important area of research."
MCP, a specially modified version of citrus pectin, is easily absorbed from the gastrointestinal tract into the circulation where it provides a number of system-wide benefits. In preclinical and clinical studies, MCP has demonstrated a number of anti-cancer actions including inhibition of cancer progression and metastasis. These effects are due largely to its ability to act as a natural inhibitor of extracellular galectin-3 — a protein that at elevated levels drives cancer proliferation, metastasis, immune evasion, inflammation, and fibrotic tissue damage. By binding and inactivating galectin-3, MCP disrupts tumor growth and metastasis, while allowing anti-cancer drugs and other adjuvants to reach target tumor cells.
In addition to its impact on galectin-3, MCP also removes toxic heavy metals, activates specific cells of the immune system and reduces inflammation. A 2011 study in the journal BMC Complementary and Alternative Medicine found that MCP enhanced the ability of natural killer cells to eliminate human leukemia cells.
Honokiol extract is a biphenyl molecule purified from the bark of the Magnolia officinalis tree, which has been used for centuries in traditional Asian medicine. Extensive research has found that honokiol has a number of potent anti-cancer mechanisms, as well as anti-inflammatory, anti-angiogenic, anti-oxidative, anti-fungal, anti-microbial and anti-viral properties. With a unique ability to cross the blood brain barrier, honokiol is also an effective anxiolytic with significant neuroprotective benefits.
When combined, MCP and honokiol extract provide substantial benefits for those who have or are at risk of developing cancer. The new patent describes the administration of honokiol and MCP in synergistic dosages to inhibit cancer formation, progression and metastasis.
Dr. Eliaz's patent is No. 8,916,541 with the U.S. Patent & Trademark Office.
To learn more about Dr. Eliaz and his work, visit http://www.dreliaz.org.
SOURCE Better Health Publishing